These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38500962)

  • 1. Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.
    Aggarwal NR; Beaty LE; Bennett TD; Fish LE; Jacobs JR; Mayer DA; Molina KC; Peers JL; Richardson DB; Russell S; Varela A; Webb BJ; Wynia MK; Xiao M; Carlson NE; Ginde AA
    Lancet Reg Health Am; 2024 Mar; 31():100693. PubMed ID: 38500962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
    Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England.
    Kirsebom FCM; Harman K; Lunt RJ; Andrews N; Groves N; Abdul Aziz N; Hope R; Stowe J; Chand M; Ramsay M; Dabrera G; Kall M; Bernal JL
    Lancet Reg Health Eur; 2023 Dec; 35():100755. PubMed ID: 38115965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.
    Zheng B; Tazare J; Nab L; Green AC; Curtis HJ; Mahalingasivam V; Herrett EL; Costello RE; Eggo RM; Speed V; Bacon SC; Bates C; Parry J; Cockburn J; Hester F; Harper S; Schaffer AL; Hulme WJ; Mehrkar A; Evans SJ; MacKenna B; Goldacre B; Douglas IJ; Tomlinson LA;
    Lancet Reg Health Eur; 2023 Nov; 34():100741. PubMed ID: 37927438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
    Liu TH; Huang PY; Wu JY; Chuang MH; Hsu WH; Tsai YW; Chang CC; Lai CC
    J Med Virol; 2023 May; 95(5):e28801. PubMed ID: 37218308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
    Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
    Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States.
    Carlson J; Foos V; Kasle A; Mugwagwa T; Draica F; Lee Wiemken T; Nguyen JL; Cha-Silva A; Migliaccio-Walle K; Dzingina M
    Value Health; 2024 Feb; 27(2):164-172. PubMed ID: 38043712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
    Chuang MH; Wu JY; Liu TH; Hsu WH; Tsai YW; Huang PY; Lai CC
    J Med Virol; 2023 Apr; 95(4):e28750. PubMed ID: 37185834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants.
    Hsu CK; Hsu WH; Shiau BW; Tsai YW; Wu JY; Liu TH; Huang PY; Chuang MH; Lai CC
    Expert Rev Anti Infect Ther; 2024 Apr; ():1-8. PubMed ID: 38568820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States.
    Sandin R; Veenstra DL; Vankelegom M; Dzingina M; Sullivan SD; Campbell D; Ma C; Harrison C; Draica F; Wiemken TL; Mugwagwa T
    J Manag Care Spec Pharm; 2023 Dec; 29(12):1290-1302. PubMed ID: 38058141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review.
    Cha-Silva AS; Gavaghan MB; Bergroth T; Alexander-Parrish R; Yang J; Draica F; Patel J; Garner DA; Stanford RH; Meier G; McLaughlin JM; Nguyen JL
    Am J Ther; 2024 May-Jun 01; 31(3):e246-e257. PubMed ID: 38691664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study.
    Basoulis D; Tsakanikas A; Gkoufa A; Bitsani A; Karamanakos G; Mastrogianni E; Georgakopoulou VE; Makrodimitri S; Voutsinas PM; Lamprou P; Kontos A; Tsiakas S; Gamaletsou MN; Marinaki S; Sipsas NV
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
    Wu JY; Chen CC; Liu MY; Hsu WH; Tsai YW; Liu TH; Pin-Chien S; Huang PY; Chuang MH; Lee MC; Hung KC; Yu T; Lai CC
    J Med Virol; 2024 May; 96(5):e29662. PubMed ID: 38727085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.